text:
Red Raider Hardball :: Texas Tech Beats Bethune-Cookman, 14-12
Share All sharing options for: Red Raider Hardball :: Texas Tech Beats Bethune-Cookman, 14-12
Texas Tech (6-1) vs. Bethune-Cookman and Washington St.
Location: Lubbock, TX
Date Start Time Texas Tech
Starting Pitcher Opponent
Starting Pitcher Result
2.25.10 4:00 p.m. Chad Bettis
W, 2-0 Patrich Goelz-Bethune-Cookman
L, 0-1 W: 12-8
2.26.10 4:00 p.m. Jay Johnson
L, 0-1 Paris Shewey-Washington St.
W, 1-0 L: 3-6
2.27.10 4:00 p.m. Brett Bruening
W, 2-0 Joey Munoz-Bethune Cookman
L, 0-2 W: 14-12
2.28.10 12:00 p.m. Jordan Stern
(0-0, 0.00) TBA-Washington St.
Outfield:
LF - Michael Reed (Sr.); CF - Taylor Ashby (Sr.); RF - Barrett Barnes (Fr.)
Infield:
SS - Joey Kenworthy (Sr.) 2ND - Garrett Totten (So.);
3RD - Nick Popescu (Jr.) 1ST - Stephen Hagen (Jr.)
C - Jeremy Mayo (So.)
DH - Scott LeJeune (So.)
*Click on the score for boxscore. Texas Tech series preview (pdf).
The Game: This series, the pitching staff has been a bit less dominating, and that's okay. Sometimes I have to remind myself that a win is a win. SP Louis Head (4.0 IP; 7 H; 5 ER; 1 BB; 2 SO) had an okay outing, although giving up 5 runs isn't ideal, while relief pitcher Brett Bruening earned the win, but his line was worse that Head's (3.0 IP; 5 H; 6 R; 5 ER; 1 BB; 1 SO). A combination of Ben Flora, Brandon Petite and Justin Cooper, pretty much shut down Bethune-Cookman throught the 8th and 9th innings. Cooper got his 2nd save of the year. Texas Tech took the lead on 1B Stephen Hagen's home run in the bottom of the 7th inning and started a rally that eventually led to a Texas Tech win. SS JOey Kenworthy (2-3; 1 HR; 2 BB; 5 RBI), DH Scott LeJeune (2-4; 2 RBI), 3B Nick Popescu (2-4; 1 HR; 3 RBI) and 1B/RF Barrett Barnes (2-4; 1 RBI) helped lead an offense that scored multiple runs in the 1st, 2nd, 4th and 7th innings.
Recaps: LAJ's George Watson writes about the pitching staff and what this win does for the character of the team:
That was due to more struggles from the back end of Tech's pitching staff. Starter Louis Head was solid for three innings but surrendered the lead with a three-run fourth, and junior right-hander Brett Bruening (2-0) gave up six runs on five hits in three innings of relief.
Tech was finally able to close out the game as freshman right-hander Brandon Petite allowed a run on two hits in 2/3 of an inning, and after allowing a walk, turned it over to junior right-hander Justin Cooper, who closed out his second save thanks to an outstanding play by Kenworthy to turn a game-ending double play.
"It was a good win for the kids' character to come back after getting beat last night, scoring some runs and being patient with a guy out there who was throwing strikes," head coach Dan Spencer said. "That's a loose bunch over there and if you don't make your pitches, they'll get on you, and that's a good lesson, and hopefully we'll learn it. It's a win and we'll take it."
Official Site Post Game Quotes:
Head Coach Dan Spencer on the late rally in game after last night:
"The three late runs were nice. (Stephen) Hagen hit the home run, we had a walk and a couple doubles. That's huge. That's the difference in the game. We were in dire need. We were in trouble. We've got to figure out a way to be better on the mound late in the game. We will worry about that a little bit. We'll talk about it after the game then we will line up and play again tomorrow. To hang around and play defense like we did, and then (Joey) Kenworthy made a great play to the end the game. (Garrett) Totten did a good job of getting to the ball. I would have liked him to go ahead and catch it clean but he had to go a ways for it anyways. It was a good win for the kids as far as character and coming back after getting beat last night and scoring some runs as well as being patient with a guy who was having a hard time throwing strikes. They're a loose bunch that bunch over there (Bethune-Cookman) so if you don't make your pitches they'll make you pay. It's a win. We'll take it."
Head Coach Dan Spencer on how the pitching staff lineup looks going into tomorrow's game:
"Thin. We need to get some innings out of (Jordan) Stern. We'll start Stern. We need to score some runs early. We were able to keep Jay (Johnson) out of the game tonight. We had to. We felt like we needed to give him a rest even though he was chomping at the bit, wanting to get the ball back and go back to work. But in the best interests of him and the long-term, we'll have Jay available again tomorrow. If we throw strikes, we'll be fine. I think we will."


For entrepreneurs we offer consultations on business idea perspectives, funding possibilities, access to EU Structural Funds and other support programmes, as well as project development and monitoring implementation thereof.
For municipalities we offer preparation of territorial development planning documents, such as sustainable development strategies and development programmes, including structured and purposeful project management.
Edo Consult team offers advisory support in the drawing up of sectoral strategic development documents and action plans to professional sectoral non-governmental organisations and cooperative societies.


text:
Manchester United ahead in massive chase for Juventus major star; Arsenal plotting huge defender offer
The latest Premier League transfer news and rumours
Updated 08:16, 9 NOV 2018
Medhi Benatia of Juventus FC
Manchester City star Leroy Sane has joked that there is no chance he could join city rivals Manchester United.
Rumours have been rife that that the talented German could make a shock switch to Old Trafford after a slow start to the season at the Etihad Stadium.
But Sane has now spoken out about the talk and insists that it is nonsense.
He said: "That won't happen! That won't happen! That won't happen at all. I am really happy here and I'm on the right side."
Sane won the PFA Young Player of the Year award last season and he says he never had any concerns about his lack of starts.
He added: "I have not been worried at all. I know what they want from me and what they expect from me and I will just try to work hard.
"I always enjoy myself. To play with these players under this coach is a really good feeling and everyone can see we enjoy it all together, playing with each other. It's fun to play with this team."
Leroy Sane celebrates his goal against Bristol City
Juventus defender Medhi Benatia is wanted by Manchester United as Jose Mourinho tries to bring in a new centre back during the January transfer window.
Tuttosport report that Jose Mourinho wants to sign the 31-year-old as he seeks experience at the back.
Benatia is frustrated with life at Juve after struggling to get game time and he could be looking for a January exit.
He has made just four league appearances and has featured once in the Champions League this season
Arsenal are also thought to be in the hunt for the defender who is valued at around £20million.
Premier League latest
2018/19 kit rankings
Richest owners
End of football streams
Latest gossip
Another possible January option for the Gunners is Nicolas Pepe from Lille.
According to reports in France from Telefoot, Unai Emery is ready to submit an offer worth £50m.
He has been one of the stars in Ligue 1 this season, having scored eight times and getting five assists.
The 23-year-old is also being tracked by Bayern Munich and Borussia Dortmund with a bidding war possible in the winter window.

redpajama_set_name: RedPajamaCommonCrawl


text:
AI Policy Leadership
Home IssueArtificial Intelligence	Comments to the Department of Commerce on Export Controls for Emerging Technologies
Comments to the Department of Commerce on Export Controls for Emerging Technologies
by Daniel Castro and Joshua New	December 13, 2018
The Center for Data Innovation has filed comments with the U.S. Department of Commerce's Bureau of Industry and Security regarding its proposed rulemaking about export controls for certain emerging technologies. The Department of Commerce is seeking comments to determine whether there are specific emerging technologies that are important to the national security of the United States for which effective controls can be implemented that avoid negatively impacting U.S. leadership in the science, technology, engineering, and manufacturing sectors. Specifically, Commerce is interested in whether to include artificial intelligence (AI) and machine learning (ML) technologies. The Center strongly urges Commerce to exclude AI and ML technologies from export controls.
Read the comments.
Daniel Castro is the director of the Center for Data Innovation and vice president of the Information Technology and Innovation Foundation. Mr. Castro writes and speaks on a variety of issues related to information technology and internet policy, including data, privacy, security, intellectual property, internet governance, e-government, and accessibility for people with disabilities. His work has been quoted and cited in numerous media outlets, including The Washington Post, The Wall Street Journal, NPR, USA Today, Bloomberg News, and Businessweek. In 2013, Mr. Castro was named to FedScoop's list of "Top 25 most influential people under 40 in government and tech." In 2015, U.S. Secretary of Commerce Penny Pritzker appointed Mr. Castro to the Commerce Data Advisory Council. Mr. Castro previously worked as an IT analyst at the Government Accountability Office (GAO) where he audited IT security and management controls at various government agencies. He contributed to GAO reports on the state of information security at a variety of federal agencies, including the Securities and Exchange Commission (SEC) and the Federal Deposit Insurance Corporation (FDIC). In addition, Mr. Castro was a Visiting Scientist at the Software Engineering Institute (SEI) in Pittsburgh, Pennsylvania where he developed virtual training simulations to provide clients with hands-on training of the latest information security tools. He has a B.S. in Foreign Service from Georgetown University and an M.S. in Information Security Technology and Management from Carnegie Mellon University.
Joshua New
Joshua New is a senior policy analyst at the Center for Data Innovation. He has a background in government affairs, policy, and communication. Prior to joining the Center for Data Innovation, Joshua graduated from American University with degrees in C.L.E.G. (Communication, Legal Institutions, Economics, and Government) and Public Communication. His research focuses on methods of promoting innovative and emerging technologies as a means of improving the economy and quality of life. Follow Joshua on Twitter @Josh_A_New.
View all posts by Daniel Castro and Joshua New
French Proposal for an "IPCC of AI" Will Only Set Back Global Cooperation on AI
Mapping Population Sizes as 3D Mountains
XBRL: How to Save a Good Idea from...
Comments to NIOSH on the Internet of Things...
Comments to NIST on AI Standards
Comments to CBP on Its Proposal to Collect...
Should Antitrust Regulators Stop Companies from Collecting So...
The EU's "Softball" Approach to Artificial Intelligence Will...
Comments to the FTC on Competition and Consumer...
How Germany and the United States Are Racing...
Sunshine Weeks Sheds Light on Open Data Opportunities
Don't Let Open Data Go Dark
Center for Data Innovation China Press EU Press India Press Japan Press Korea Press Global Press Singapore Press U.S. Press Daniel Data for Development
The EU Needs to Reform the GDPR To Remain Competitive in the Algorithmic Economy
Why the United States Needs a National Artificial Intelligence Strategy and What It Should Look Like
How Policymakers Can Foster Algorithmic Accountability
The Impact of the EU's New Data Protection Regulation on AI
Blocked: Why Some Companies Restrict Data Access to Reduce Competition and How Open APIs Can Help
How National Governments Can Help Smart Cities Succeed
The State of Data Innovation in the EU
The Best States for Data Innovation


It would be best if you post your question as a new topic in the General section where it will get more attention and hopefully some suggestions towards resolving your problem (this area is just for introductions).
I'm a new user with Mach, just installed my lic yesterday after trying out the demo mode for several weeks, nice piece of software..
it's nice to have the machine up and running,need to dial it in just a little more but i'm very close now..
thats about it,just a quick intro for me...I will be reading the forums,watching the videos and asking questions when I cant find the answer to something on my own.
I always try first... seems like there is plenty of support here and many good friendly people willing to help..
I really like your lithopanes, the grim reaper will be one of the first I do..
My Name is Cuong Le and I am a totally new in CNC world. Hope to learn from all of you. Living Aloha Oregon, would love to meet some local friends, mentors.
I am moving over from LinuxCNC. It's not that its bad software but more or less it only supports G93 Inverse Timing and the lower end CAM software doesn't support G93 yet. Some CAM packages say they never will support it and yet others have never heard of RS-274NGC or even NIST for that matter. So, loving my 4 axis machine I am dual booting with "Winders" and trying to get set up and start cutting some cool stuff!
I am new here today. I have been using Mach3 for a few months now for my home made benchtop CNC machine. I am making small aluminium parts.
Although of generous years, I haven't retired and work about full time with a company that converts customer's vans into campervans. It struck me that the repetitive cabinet making was an ideal subject for a CNC cutter. Never seen one im my life but a quick look round the internet and in particular Youtube, it seemed like something I might want to build. So, here I am, Brian Withers from England, built the electronics box with the steppers and motor drivers and a PC running XP and the use of a demo version of Mach3.
Waiting for some cheap parts from China which may not be to everyone's taste but generally half the price of UK parts for the same job but have already assembled a few mechanical parts.
I ran into a few problems getting the motors to drive and used this board and thanks to Tweakie have crossed that bridge.
I expect that there will be quite a steep learning curve with Mach3 so I'm sure I will be back.


We all know that being in good shape mentally as well as physically is vital to a healthy, productive and happy workforce. There are times where everyone experiences the pressures of life, but there are some situations that can leave employees feeling so overwhelmed and stressed, it impacts on their ability to perform their job.
We provide assurance to all stakeholders by having a three tiered system in place for quality assurance. Furthermore, we actively assess and manage risk issues, referring or signposting clients to their GP, alternative NHS resources or support services where appropriate. Themes, trends and risks are highlighted appropriately which can then be used in wellbeing campaigns and training initiatives.
Our counselling service is versatile and corporately focused which is highly regarded by our customers, trusted by our clients that ultimately lead to great results for everyone. A sound return on investment.
Get in touch to see how we can help support you and your staff.


text:
<?php

/**
 * sfPHPUnitTestBrowser observer interface
 *
 * @package    sfPhpunitPlugin
 * @author     Maxim Oleinik <maxim.oleinik@gmail.com>
 */
interface sfPHPUnitTestBrowserObserverInterface
{
    public function notify($method, sfBrowser $browser);
}

redpajama_set_name: RedPajamaGithub


text:
My CF - login / Košík 2
Café Rudolfinum
Families & Schools
Preschools and schools
Orchestral Academy
Čeština /
Penguins at the Rudolfinum
Czech Philharmonic
The programme for children is based on a musical part but also on a spoken word that will be given in Czech language only. The program will not be supplied with English subtitles.
Duration of the programme 1 hod
Rudolfinum — Dvorak Hall
Rudolfinum
Czech Republic Praha 1
Tickets and contact information
Customer Service of Czech Philharmonic
E-mail: info@czechphilharmonic.cz
Customer Service office hours are on weekdays from 09:00 a.m. to 06:00 p.m. July, August from 09:00 a.m. to 03:00 p.m.
Because of their tailcoats, orchestra musicians somewhat resemble penguins, especially when seen with the eyes of children. For the seventh time, the actor Pavel Liška will be examining the world of orchestral musicians and their music. And naturally, there will be a curious and enthusiastic audience of children. Together, they have already discovered what different kinds of music sound like, what a conductor is needed for, and why one does not talk at concerts. But they have also been able to experience what it is like to conduct an orchestra, to sing "Let's Rejoice and Be Merry" from The Bartered Bride accompanied by an orchestra, to create the newest music together with the musicians of the Philharmonic, or to witness a performance by a blind pianist. You are invited to a new, entertaining, and educational programme by Alice Nellis for parents with children!
Alice Nellis
author and director
Vojtěch Jouza
Czech Student Philharmonic
The best of the Rudolfinum directly to your e-mail.
Hesitating? See what it looks like. Take a look
Your email is safe for us. The Czech Philharmonic will only use the address for the purpose of distributing the Magazine. More about privacy
© Czech Philharmonic


text:
DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis
Clinical and epidemiological research
Extended report
Y P M Goekoop-Ruiterman1,
J K de Vries-Bouwstra2,
P J S M Kerstens3,
M M J Nielen3,
K Vos3,
D van Schaardenburg2,3,
I Speyer4,
P E H Seys5,
F C Breedveld1,
C F Allaart1,
B A C Dijkmans2,3
Leiden University Medical Centre, Leiden, The Netherlands
VU Medical Centre, Amsterdam, The Netherlands
Jan van Breemen Institute, Amsterdam, The Netherlands
Hospital Bronovo, The Hague, The Netherlands
Hospital Lievensberg, Bergen op Zoom, The Netherlands
Correspondence to Mrs Y P M Goekoop-Ruiterman, Leiden University Medical Centre, Department of Rheumatology C-1-R, PO Box 9600, 2300 RC Leiden, The Netherlands; y.p.m.goekoop{at}lumc.nl
Objectives: To compare the efficacy of Disease Activity Score (DAS)-driven therapy and routine care in patients with recent-onset rheumatoid arthritis.
Methods: Patients with recent-onset rheumatoid arthritis receiving traditional antirheumatic therapy from either the BeSt study, a randomised controlled trial comparing different treatment strategies (group A), or two Early Arthritis Clinics (group B) were included. In group A, systematic DAS-driven treatment adjustments aimed to achieve low disease activity (DAS ⩽2.4). In group B, treatment was left to the discretion of the treating doctor. Functional ability (Health Assessment Questionnaire (HAQ)), Disease Activity Score in 28 joints (DAS28) and Sharp/van der Heijde radiographic score (SHS) were evaluated.
Results: At baseline, patients in group A (n = 234) and group B (n = 201) had comparable demographic characteristics and a mean HAQ of 1.4. Group A had a longer median disease duration than group B (0.5 vs 0.4 years, p = 0.016), a higher mean DAS28 (6.1 vs 5.7, p<0.001), more rheumatoid factor-positive patients (66% vs 42%, p<0.001) and more patients with erosions (71% vs 53%, p<0.001). After 1 year, the HAQ improvement was 0.7 vs 0.5 (p = 0.029), and the percentage in remission (DAS28 <2.6) 31% vs 18% (p<0.005) in groups A and B, respectively. In group A, the median SHS progression was 2.0 (expected progression 7.0), in group B, the SHS progression was 1.0 (expected progression 4.4).
Conclusions: In patients with recent-onset rheumatoid arthritis receiving traditional treatment, systematic DAS-driven therapy results in significantly better clinical improvement and possibly improves the suppression of joint damage progression.
http://dx.doi.org/10.1136/ard.2008.097683
In patients with recent-onset rheumatoid arthritis, several combinations of disease-modifying antirheumatic drugs (DMARDs) or biological agents1 2 3 4 5 6 7 8 9 have proven superiority over initial monotherapy in improving clinical and radiographic outcomes. In the recently performed BeSt study,10 four different treatment strategies were compared in a setting of tight disease control. Patients treated with initial combination therapy with either prednisone or infliximab had a more rapid clinical response than patients treated with sequential monotherapy or step-up to combination therapy. After 1 year, changes in the physical function and the percentage of patients in clinical remission were comparable for all treatment groups. To achieve this, treatment had to be adjusted more often and for more patients in the initial monotherapy groups than in the initial combination therapy groups. We hypothesised that the systematic measurements of disease activity with adjustments to treatment according to a fixed protocol aiming at a Disease Activity Score (DAS) ⩽2.411 are the reasons for the remarkable improvement in the initial monotherapy groups after 1 year of follow-up.
To investigate this further, we compared the results of the patients receiving sequential monotherapy or step-up to combination therapy in the BeSt trial10 with the results of similar patients with rheumatoid arthritis who received routine care.
All patients fulfilled the American College of Rheumatology 1987 criteria for rheumatoid arthritis.12 Group A consisted of patients participating in the BeSt study, who were treated with the traditional strategies—that is, sequential monotherapy (group 1) or step-up combination therapy (group 2). Inclusion criteria were as follows: age ⩾18 years, a disease duration ⩽2 years, ⩾6/66 swollen joints, ⩾6/68 tender joints and either an erythrocyte sedimentation rate (ESR) ⩾28 mm/h or a global health score ⩾20 mm on a visual analogue scale of 0–100 mm (0 = best, 100 = worst). Patients in the BeSt study were derived from two university and 18 peripheral hospitals in the western part of the Netherlands between April 2000 and August 2002. Group B consisted of all patients from the databases of the Early Arthritis Clinic of Leiden University Medical Centre (LUMC) and the Jan van Breemen Institute (JBI) in Amsterdam, who were diagnosed with rheumatoid arthritis and met the inclusion criteria of the BeSt study (see above). In the Early Arthritis Clinics, Disease Activity Scores of 28 joints, radiographs of hands, wrists and feet and several questionnaires are collected prospectively at regular intervals. During the inclusion period of the BeSt study, all eligible patients were enrolled in this study. For group B, all patients from the period before (January 1998–March 2000) and after the BeSt study (August 2002–December 2004) were included in this analysis.
Only patients with baseline and 1-year follow-up data of the Dutch version of the Health Assessment Questionnaire (HAQ),13 Sharp/van der Heijde score (SHS) for radiographic joint damage,14 or both, were included in this comparison. The DAS28 was not used as an inclusion criterion.
In total, 247 patients were included in the BeSt study in the initial monotherapy groups 1 and 2. For the current analysis we excluded 10 patients who withdrew within the first year of follow-up and an additional three patients, because of missing change scores for both HAQ and SHS.
In group A, treatment adjustments were standardised and based on the DAS, obtained every 3 months, with the goal to achieve low disease activity (DAS ⩽2.4).15 Patients assigned to sequential monotherapy started treatment with methotrexate, followed subsequently, in the case of a persistent DAS >2.4, with sulfasalazine, leflunomide and methotrexate with infliximab. If the DAS was ⩽2.4 for at least 6 months, medication was tapered to the last established drug at a maintenance dose. Patients assigned to step-up combination also started treatment with methotrexate alone, followed subsequently, in the case of a persistent DAS >2.4, with methotrexate with sulfasalazine; methotrexate with sulfasalazine and hydroxychloroquine; methotrexate with sulfasalazine, hydroxychloroquine and prednisone; and methotrexate with infliximab. If the DAS was ⩽2.4 for at least 6 months, the last added drug was tapered first, until monotherapy at a maintenance dose remained. Parenteral corticosteroids were not allowed and low-dose oral corticosteroids were allowed only as described in the treatment protocol for the step-up combination group. A detailed description of the protocol has been published previously.10
In group B, treatment, including the use of corticosteroids and biological agents, was left to the discretion of the treating doctor.
In both treatment groups, assessments were made by research nurses every 3 months during the entire follow-up period. The primary clinical end point was functional ability, measured by the HAQ, with higher scores indicating more severe loss of physical function.13 The secondary clinical end point was the mean disease activity score in 28 joints (DAS28)16 and the remission percentage defined as DAS28 <2.6. The primary radiographic end point was the change from baseline to 1 year in the total SHS, ranging from 0 to 448.14 Radiographs of hands, wrists and feet, at baseline and at 1-year follow-up, were scored independently by two readers (JV and YG) blinded to the patient's identity, treatment group and sequence of the films. The mean score of the two readers was used for the analysis. The intraobserver coefficients were 0.84 and 0.87 and the interobserver coefficient was 0.96. Erosive disease was defined as a mean erosion score >0.5. Progression of joint damage was defined as a change in total SHS greater than the smallest detectable change,17 which was 4.10. The predicted joint damage progression during the first year was extrapolated by dividing the baseline total SHS by the symptom duration. This extrapolation has been described previously in a study using the Larsen score for joint damage progression.18 Suppression of joint damage progression was defined as the median observed progression minus the expected progression.
All available data were used for the analyses. Measurements with a Gaussian distribution are expressed as mean and standard deviation (SD), and measurements with a non-Gaussian distribution are expressed as median and interquartile range (IQR). Outcomes of patients in groups A and B were compared, using the Student t test, Mann–Whitney U test and χ2 test, where appropriate. Linear regression analysis was used to describe the effect of the treatment group on the change in primary outcomes (HAQ and SHS), with 95% confidence intervals (95% CIs) with correction for the baseline differences: symptom duration, rheumatoid factor (RF) positivity, DAS28, baseline SHS and baseline HAQ. The DAS28 was used instead of the separate core set variables (tender and swollen joint count, ESR and visual analogue scale), because the databases provided different total joint scores and not scores per joint.
A subgroup analysis on the primary outcome measurements HAQ and SHS was performed using only the patients from the LUMC and JBI (93 patients in group A and all 201 patients in group B), using the Student t test and the Mann–Whitney U test, respectively.
A total of 435 patients with recent-onset, active rheumatoid arthritis was included (234 in group A, 201 in group B). Group B consisted of 121 patients from the period before the initiation of the BeSt study and of 80 patients from the period after the BeSt study. HAQ scores were available for 228 patients (97%) in group A and 192 patients (96%) in group B, DAS28 scores were available for 232 patients (99%) in group A and 166 patients (83%) in group B, and baseline SHS was available in 229 patients (98%) in group A and 191 patients (95%) in group B.
Data for all other demographic and disease characteristics were available in over 98% of patients. Patients for whom data on DAS28 were missing had a lower median baseline SHS than patients in whom these data were complete (1.5 vs 3.0, p = 0.011). There were no other differences in baseline characteristics between patients with missing and complete data.
At baseline, the average age of patients was 54 years, 72% were female, the mean HAQ was 1.4, the mean DAS28 was 5.9 and the median SHS was 3.0. Patients in group A had a longer median disease duration than patients in group B (0.5 vs 0.4 year, p = 0.016), a higher mean DAS28 (6.1 vs 5.7, p<0.001) and a higher median ESR (39 vs 31 mm/h, p = 0.033). More patients in group A were RF positive (66% vs 42%, p<0.001) and more had erosive disease (71% vs 53%, p<0.001) in comparison with patients in group B (table 1).
Baseline demographic and disease characteristics
Overall, clinical outcomes had improved after 1 year. The mean HAQ improvement was 0.6, the mean DAS28 improvement was 2.4 and the mean ESR decrease was 15 mm/h (table 2).
Change in patient outcomes during 1-year follow-up
Despite higher baseline scores, patients in group A had better clinical outcomes after 1 year of follow-up than patients in group B. The mean HAQ improvement was 0.70 in group A versus 0.55 in group B (p = 0.029) (fig 1A), the mean DAS28 improvement was 2.7 in group A versus 1.9 in group B (p<0.001) (fig 1B) and the median ESR improvement was 19 mm/h in group A versus 13 mm/h in group B (p = 0.011). The percentage of patients in clinical remission (DAS28 <2.6) after 1 year was 31% in group A versus 18% in group B (p<0.005).
Mean Health Assessment Questionnaire (HAQ) and Disease Activity Score in 28 joints (DAS28) of the patients with DAS-driven therapy (group A) and routine care (group B).
In the linear regression analysis, the difference in HAQ improvement between the groups was 0.155 (0.015–0.294). After correcting for baseline differences in symptom duration, RF positivity, DAS28, SHS and HAQ, the difference in HAQ improvement was 0.143 (0.004–0.282), p = 0.044.
For the subgroup of patients from LUMC and JBI, patients treated with DAS-driven therapy had better clinical outcomes, but owing to the small sample size, no statistically significant differences were seen (data not shown).
Radiographic outcomes
Radiographs of hands, wrists and feet of 410 patients (94%) at both baseline and 1-year follow-up were available for analysis (224 patients in group A and 186 patients in group B). Based on the SHS score at baseline and the duration of symptoms at baseline, the expected progression of radiographic joint damage was calculated for patients in both groups. In group A, the expected progression after 1 year was 7.0, whereas the observed progression was 2.0. In group B, the expected progression was 4.4, whereas the observed progression was 1.0 (p<0.001 for expected progression, p = 0.006 for observed progression) (fig 2). The larger difference between the expected progression and observed progression in group A suggests that the suppression of joint damage progression was better in this group than in group B, although this was not statistically significant (p = 0.126).
Expected and observed progression of the Sharp/van der Heijde score (SHS) for radiographic joint damage for Disease Activity Score-driven therapy (group A) and routine care (group B).
In the linear regression analysis, the difference in the mean SHS progression was 2.32 (0.36–4.28) p = 0.020. After correcting for baseline differences in symptom duration, RF positivity, DAS28, SHS and HAQ, the difference in SHS progression was −0.42 (−2.23–1.40), p = 0.652—that is, in favour of the DAS-driven treatment group, but not statistically significant.
At baseline, significantly more patients in group A had erosive disease (group A 71%, group B 53%; p<0.001). After 1 year, the difference in percentage of patients with erosive disease was less distinct (group A 81%, group B 74%; p = 0.091).
During the first year, more patients in group A than in group B had received DMARD therapy, including prednisone (100% vs 89%). The median (IQR) number of DMARDs per patient was 2.0 (1.0–3.0) in group A and 1.0 (1.0–2.0) in group B. In group A, all patients started with methotrexate. As dictated by the protocol, patients in group A switched medication if the DAS was >2.4, corresponding with a DAS28 >3.6. The following antirheumatic drugs were prescribed during the first year: sulfasalazine in 58% of patients, leflunomide in 20%, antimalarial drugs in 15%, low-dose prednisone in 7% and infliximab in 11% of patients. In group B, methotrexate had been prescribed in 54% of patients, sulfasalazine in 32%, prednisone in 21%, antimalarial agents in 19%, ciclosporin A in 3%, leflunomide in 1%, gold in 1%, etanercept in 1% and adalimumab in 1% of patients.
This comparison of clinical and radiological outcomes in patients with recent-onset rheumatoid arthritis receiving traditional antirheumatic therapy shows that patients benefit from systematic monitoring of disease activity and standardised treatment adjustments compared with routine care. DAS-driven therapy adjustments result in significantly better clinical outcomes than routine management. These results are consistent with previous studies, which demonstrated that intensive management is more effective than routine care19 20 and that adherence to treatment guidelines improves outcome.21
Our observations are the result of comparing treatments for patients with recent-onset rheumatoid arthritis in the BeSt study (initial monotherapy with antirheumatic drugs) with a cohort of patients receiving routine treatment. We included all patients who would have met the inclusion criteria of the BeSt study within a period of 2 years before and after the inclusion period of the BeSt study from the Early Arthritis Clinics databases of the LUMC and the JBI, which were the main contributors of patients for the BeSt study. Nevertheless, when we compared the baseline characteristics, patients in the routine care group had a milder disease at baseline with fewer patients testing positive for RF, a lower disease activity and less radiographic joint damage than the patients in the BeSt study. The differences in baseline demographic and disease characteristics between patients in the BeSt study and patients in the routine care group were smaller when only patients included in the LUMC and JBI were analysed, suggesting selection bias in the BeSt study of patients with worse disease characteristics, which appears to be most common in the other participating (peripheral) centres.
A second important difference between group A and group B is the medication received. Despite the fact that both the LUMC and the JBI are specialised centres for patients with rheumatoid arthritis, patients in the routine care group less often received methotrexate, which is now considered to be the anchor drug in RA treatment.22 In part, this may be explained by milder disease characteristics in the routine group at the time of diagnosis. On the other hand, oral prednisone was prescribed more often, and low-dose steroids are effective in suppressing the rate of joint damage progression.23 24 25 Over time, novel insights might have influenced treatment choices in the routine care group, but the number of patients treated before and after the inclusion period of the BeSt study was too small to find significant differences in drug prescription patterns.
In our opinion, the differences between the two groups only increase the strength of the observation that despite a worse prognosis patients treated in the BeSt study with DAS-driven therapy show more clinical improvement than patients receiving routine care, who had a better initial prognosis and more often received oral corticosteroids.
At baseline, significantly more patients in the DAS-driven group had erosive disease. During the first year, more patients in the routine care group progressed from non-erosive to erosive disease, resulting in a comparable percentage of patients with erosive disease after 1 year of treatment. Furthermore, the rate of progression after 1 year appears to be better suppressed in the DAS-driven group than in the routine care group, although one might argue that this is the result of regression to the mean. The differences in disease severity at presentation and drug prescription probably explain why we did not find a statistically significant difference between the groups.
We conclude that systematic DAS-driven therapy results in better improvement of clinical outcomes and results in good suppression of joint damage progression.
We thank all patients, all rheumatologists and trainee rheumatologists who participated in the BeSt study and/or the Early Arthritis Clinic, and all research personnel for their contribution to this article.
Boers M,
Verhoeven AC,
Markusse HM,
. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309–18.
Breedveld FC,
Emery P,
Keystone E,
. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004;63:149–55.
Weisman MH,
Kavanaugh AF,
. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26–37.
Calguneri M,
Pay S,
Caliskaner Z,
. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. Clin Exp Rheumatol 1999;17:699–704.
Genovese MC,
Bathon JM,
Martin RW,
. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443–50.
Gerards AH,
Landewe RB,
Prins AP,
. Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. Ann Rheum Dis 2003;62:291–6.
Marchesoni A,
Battafarano N,
Arreghini M,
. Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatology (Oxford) 2003;42:1545–9.
Mottonen T,
Hannonen P,
Leirisalo-Repo M,
. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353:1568–73.
St Clair EW,
van der Heijde DM,
Smolen JS,
. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432–43.
Goekoop-Ruiterman YP,
de Vries-Bouwstra JK,
Allaart CF,
. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381–90.
van 't Hof M,
van Riel PL,
. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579–81.
Arnett FC,
Edworthy SM,
Bloch DA,
. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
Siegert CE,
Vleming LJ,
Vandenbroucke JP,
. Measurement of disability in Dutch rheumatoid arthritis patients. Clin Rheumatol 1984;3:305–9.
Nuver-Zwart IH,
. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1:1036–8.
Felson DT,
Anderson JJ,
. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35.
Prevoo ML,
van 't Hof MA,
Kuper HH,
. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
Bruynesteyn K,
Kostense P,
. Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis 2005;64:179–82.
Wick MC,
Lindblad S,
Weiss RJ,
. Estimated prediagnosis radiological progression: an important tool for studying the effects of early disease modifying antirheumatic drug treatment in rheumatoid arthritis. Ann Rheum Dis 2005;64:134–7.
Grigor C,
Capell H,
Stirling A,
. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263–9.
Verstappen SM,
Jacobs JW,
van der Veen MJ,
. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443–9
Fransen J,
Laan RF,
van der Laar MA,
. Influence of guideline adherence on outcome in a randomised controlled trial on the efficacy of methotrexate with folate supplementation in rheumatoid arthritis. Ann Rheum Dis 2004;63:1222–6.
Pincus T,
Yazici Y,
Sokka T,
. Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003;21:S179–85.
Svensson B,
Boonen A,
Albertsson K,
. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 2005;52:3360–70.
van Everdingen AA,
Siewertsz Van Reesema DR,
. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002;136:1–12.
Wassenberg S,
Rau R,
Steinfeld P,
. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:3371–80.
Funding This study was funded by a grant from the Dutch College of Health Insurances (College Voor Zorgverzekeringen) with additional funding provided by Schering-Plough, BV and Centocor.
Competing interests CFA and FCB have received lecture fees from Schering-Plough; BACD has received funds for research and lecture fees from Schering-Plough.
Ethics approval Ethics committee approval from all participating centres.
Patient consent Patient consent received.
BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved.
EULAR textbooks
Copyright © 2020 BMJ Publishing Group Ltd & European League Against Rheumatism. All rights reserved.


text:
Нижні Карамали́ (, ) — присілок у складі Стерлібашевського району Башкортостану, Росія. Входить до складу Бакеєвської сільської ради.

Населення — 29 осіб (2010; 40 в 2002).

Національний склад:
 росіяни — 72%

Примітки

Посилання
 На Вікімапії

Населені пункти Стерлібашевського району
Присілки Башкортостану

redpajama_set_name: RedPajamaWikipedia


i just had my daughter on the 19th and my stress and anxiety is sky high...and then on top of that i have the flu and so does my other daughter....this is awful..i'm tired from flu on top of tired from breastfreeding and having a infant.
Omg some of these are just awful. For real the only way a author can make more content is if you help them with making their load smaller. Meaning patreon.
yes unless tumblr back pedals here soon they are more than canceled they will be some forgotten place like myspace.
Don't push to hard. don't want to make it worse.
Aw thank you. She is going as a black cat.
um what about those of use who can't read Russian?
not using a third webcomic site. I've already been dragged into using tapas. to many sites.
@SpaceWitch: Aw omg this made my day..Thank you.
@Ledraali: Most good ones are...My friend who i'm starting a comic with is the same way.
The person above is very rude. So what if there is a straight char in the comic?!


Totally OT, but SO cute!!
Thank you for posting this Shelagh! It's great!
Boogie Bird! I love it!
I think that cockatoo is just too cute, and a pretty good dancer too!
A former neighbor had one of these birds, and he like to dance, as well.
Find all posts by Carey N.
Find all threads started by Carey N.


The Blair design is a classic round Cape-Lilac Mahogany dining or entry table in a relaxed take on French Regency /Restoration style. Vintage features include a triform, pedestal base on a raised plinth with tailored rectangular feet. Blair's virtues include deep, curving raised-panel carving on the pedestal and top apron. Matched veneers radiate out from the center of the top.


A high quality solvent with excellent cleaning properties. It is quick drying and will remove most contaminants such as grease, finger marks, labels etc, without causing any damage to the plastic surface.
Designed for cleaning most PVCu including window frames and garden furniture.
Do you have a question about PVCu Solvent Cleaner ? We would like to help.


What do YOU think about the Somervell County Hospital District Vote for Glen Rose Medical Center?
Open comments today-sign up and post what you think-comments moderated to weed out spam.
Let me recap what *I* think.
Didn't know what the hospital district even was until I attended the Town Hall Gary Marks did last week. I understand he did another one at Glen Lakes in the last few days and I think there's another coming up on February 3. Don't think it's right that early voting starts BEFORE all the Town Hall informational hearings are held. Don't think it's right that the actual voting day is Valentine's Day, only because, at least for some, there are obvious distractions. I would like it better if the whole process to put it on the ballot had been done AFTER some informational meetings.
Have spoken here about some of the details and posted audio of the meeting. Thought we were getting a copy of the slideshow from Marks but haven't yet so will put video snapshots of the slides.
Seems to me, cutting through all the fluff, although we can't know this for sure because the hospital/medical center is operated by a private foundation, that the Glen Rose Medical Center can't be run without public taxes. Right now it's run, again, by a private foundation and apparently doesn't make a profit. Why do I think that? Because they have gone at least twice that I know of to Chet Edwards to get earmark money, and, in March, went to the Somervell County taxpayers to ask for a 14 million plus certificate of obligation to pay for an expansion. That changed the amount they paid to the county from $1.00 per year (plus another $1.00 for the nursing home) to, generally speaking, 75,000 per year plus the $1.
Some questions that arise because of knowing this. We do not know what patients are charged for various procedures versus the surrounding clinics. Is there a difference? If so, what are those differences and are the prices for procedures higher because it is THE clinic/hospital in Glen Rose? We don't know what Glen Rose Medical Foundation charges for lease space for the doctors who work from that location. Mr Marks said there is no compensation (let's call it a spiff or kickback) to any doctor based on referrals to the GRMC for procedures (for example, that might involve the radiology department). But, less tangibly, can we be sure that unnecessary services are not being pitched to patients in order to bring in money? Now, when I say that, I suspect that ANY medical center in the area (or the nation, for that matter) would likely do the same thing. I went to the dentist in Granbury a few years ago and definitely thought i was being pitched services in order to pay for the fancy equipment the dentist had in the office.
What would happen if the hospital district does nOT pass and it remains in the control of the county? They, either way, have a vested interest in wanting to see the hospital succeed, especially since they just passed, this last year, that certificate of obligation for 14 mil. If the hospital somehow defaulted, what would happen? Or, suppose the hospital was sold off to some other entity, would that entity have to take the COO as a condition? I do think that the hospital, as an entity, would remain, and be bought by someone else IF conditions were that dire. But maybe I'm wrong.
I mentioned before that I was concerned that there mgiht be an attempt to keep some operational expenses, including doctors, nurses salaries, leases, etc private. But I would think that cannot be if the taxpayer is funding it. I looked at the Texas Attorney General website last night on that and seems like open transparency is the rule for hospital districts and any attempt to use the board as a front piece to a private medical foundation would fail.
If there were no hospital district, the county would still have the obligation to fund a certain percentage of their budget for the indigent. The only thing that changes for THAT part of the budget is a bucket change-ie, from the county bucket to the hospital bucket. But then, there would be additional taxes on top of that, which could also change shoudl the hospital district want to raise the cap (remember, in Texas, the cap is 75 cents per 1000). If, say, an election was poorly attended, it might be an easy thing to keep raising the taxes. How many people attended the hearing about the 14 million?
As a side note, we know that our precinct commissioner, Mike Ford, is president of the Roger Marks Foundation. Now, that is NOT the Glen Rose Medical Foundation, and we are not aware of any direct ties between the two as far as operating the hospital. But the appearance is not good and we think that Mr. Ford should recuse himself from any votes or actions that involve the hospital district, given that Roger Marks was Gary Marks dad.
Anyway, again, we welcome your comments.
1. Businesses usually borrow money to expand. This does not mean anything except That they don't have 14 million laying around. If GRMC is not in the red for at least the last quarter, I would be shocked. Most other healthcare systems are.
2. I'd be willing to bet that their charges are in line with others, otherwise, how could they collect reimbursements from Insurance and Medicare? There is very strict guidelines for this.
3. Unnecessary procedures? This problem is endemic to the healthcare system in general and is perpetuated by younger doctors who don't know how to do a physical. There is no reason to believe that GRMC is any worse than the rest of them on this.
4. Default? I imagine that the reason GRMC is wanting to become a Hospital District (a very common structure) is because of the many uninsured or underinsured patients that grace its doors. Yes, they want financial help so they WON'T default. Since healthcare has become a business, first and foremost, if GRMC does not continue to expand its services, it won't survive.
5. If GRMC is bought by an outside corporation, there is no guarantee that anything would improve (my opinion based on my experience) and could be quite the opposite. What if?
6. Would you please explain how Mike Ford's tenure as president of the Roger Marks Foundation is a conflict of interest? Apparently, it is raising money that benefits GRMC. What's wrong with this?
1. I don't disagree. But I don't think it's always in the business of the taxpayer to loan money to private entities. When Somervell County thought about loaning 14.5 mil to GRMC/GRMF, they had to have a couple of hearings to see if anyone had objecttions to loaning taxpayer money to a private foundation. The fact that there wasn't a lot of attention paid, particularly when it was in the heat of the primaries, doesn't mean there woudlnt' have been objections had people realized.
2. I don't know. Neither do you.
3. I also don't disagree with you about this. The healthcare industry is rife with stuff like this.
4. Right, They want taxpayer money to fund it. I might be mistaken about this, but it sounded to me, on Monday night, that it is a policy of GRMC to not ask if people can pay before giving them care, while other hospitals do. And then they can't collect from the indigent, quite a lot of whom apparently come over from neighboring counties. One of hte questioners on Monday also asked a good question, which is, perhaps GRMC doesn't need to try to be a larger facility but should lower expectations; Even Dr Davis said that for certain things people are going to be airlifted out right away and sent to Fort Worth, etc.
5. I'm not saying that I think that the hospital district should NOT be run by GRMC or by an outside corporation. What I am saying that, because this would then become a taxpayer issue instead of a private foundation running it, I believe there should be a set of qualifications drawn up and bidding taken. Not just on who's the cheapest but who would meet critieria for a price. Could be GRMC would fit that. But I do not agree with the idea that the board should just automatically attempt to contract with GRMC again after being elected, just because. i also don't agree with bypassing bid systems with congressmen *securing* money for entities.
6. I don't think you saw the post where I spoke with Mike Ford the other day and he told me that the Roger Marks foundation has not ever donated money to the GRMC/GRMF but only uses the money for scholarships. So it is not a conflict of interest in that case.
4 - avoter 4 Feb 2009 @ 10:12:04 PM I think "salon" is now on to the chief issue in this whole ordeal. The underlying issue IS the maintaining of a monopoly. How long will it take for us Somervell County residents to realize that health care delivery in this county has been carefully monopolized by those (or he) who runs GRMC. Competition IS NOT a welcome sight to GRMC. This turns out to be a great shame and a greater disservice to us all. And why is it that so many have taken the bait about the function of the hospital being at risk. No matter which way this vote goes, the hospital will continue to function, and Mr. Marks will be the one in control. The actual meaning of the vote boils down to being a vote of confidence for Mr. Marks. So, the result will determine whether or not other health care providers (like a private Lab or X-Ray businesses) consider Glen Rose as "Fair Ground" on which to compete. Lord knows, our taxes are already going to sustain and empower a private foundation's monopoly. If we vote in a tax district, our very own tax money will further ensure unfair advantage and monopoly for GRMC. Just think, local competitors (like, say, a Dr. who is not affiliated with GRMC) will be forced to pay TAXES to sustain the very entity that is actively hoping and trying to drive them out of business (which is GRMC's/Mr. Marks' goal). So much for the free market. And so much for fair pricing in our own county. I remember a few months ago when GRMC's obvious ally, The Glen Rose Newspaper (Mr. Marks' mouthpiece of late) asked "Where are the Price Wars?" about the high gas prices locally. Well, they need to ask the same of GRMC. But is becomes a rhetorical question, because GRMC has no need to lower very high prices (I challenge you to call Quest Labs or One Source Diagnostics to find how low prices can be) because THERE IS NO COMPETITION. I think we need to vote to allow GRMC to hold its own WITHOUT MORE TAXES (in other words NO to the hospital district), and hope for new health provider businesses to establish here. Wouldn't it be wonderful to do business with a motivated provider who will not mess up your billing and turn you over to a collections agency before your head could spin? Wouldn't it be wonderful to simply have a local choice when the doctor orders X-Rays or MRI? Maybe a single-minded business would bring in a better MRI? Maybe we could pay 1/2 to 1/10 of GRMC's price LOCALLY? (Again, please compare the other's prices, it may be worth the 16 mile drive to Quest or One Source) Maybe? Well, no chance until the monopoly (and hopeful 3 county empire) is placed on level ground, where competitors can get some footing. A NO vote buys us some time to really consider the issue. And a NO vote will not close our hospital or put more anyone out of a job. Let's be reasonable and rational, please.
One more short note on that-do you agree, in a different context, with ending, at the federal level, congress awarding no bid contracts?
No-bid contract is a popular term for what is officially known as a "sole source contract." A sole source contract implies that there is only one person or company that can provide the contractual services needed and that any attempt to obtain bids would only result in one person or company being available to meet the need.  It is awarded usually, but not always, by a government after soliciting and negotiating with only one firm (see 48 CFR § 2.101). These contracts can be negotiated much more quickly than a typical competitive contract but they are often fraught with suspicion that the company used illegal or immoral means to exclude competitors (usually cronyism or bribery).
Or, as I mentioned in a different post, with congressional representatives allowing companies that want money to bypass the government grants program by earmarking the money directly?
humanbeing, about #5 above, when did GRMC get the upper hand in Pecan Plantation? Before Lake Granbury Medical Center could gain momentum (after Hood County General Hospital sold out to a private coorporation). And nowdays, who is Mr. Marks greatest fear? Yep, LGMC. The privately run, for profit hospital, is improving more and more. Are they out-competing GRMC? Maybe. It sure appears that Mr. Marks is worried by them. He has taught us all that we must keep our hospital local. Remember who started the fight in Hood County? That would be GRMC. Now GRMC is running scared of LGMC. We could conclude that LGMC is more motivated to be competitive and provide a service that people will CHOOSE to return to (they obviously realize that health care service is up for the client's choosing). In Somervell County, GRMC assumes you do not have a choice and they assume (accurately) that we here in little ole Somervell County are ignorant of the fact that as soon as a doctor mentions that you need a service, there exists a choice of where you get that service. The patient is the most powerful player in this decision, and doctors know this. (By the way, why don't the doctors here offer any type of lab or X-Ray service. I sincerely beg you to research and respond to this. I know the answer.) Anyway, it all get back to the monopoly issue and people scratching each other's backs. Have you asked any of the Hood County Officials how they view the change in operation there? Now I agree that you never know how an outside company would do here, but it is more likely to be a better run and differently motivated desire than our current situation.
And about #4, I think it could be proven that the enitre plan regarding the $14.5 Million CO was to do it quietly and quickly, then to immediately get this hospital district going. Think about it. Last March, Dr. Coker was already gone, Dr. Snider was already gone, Dr. Hess was already gone (and they were not "recruited" by LGMC until after their decisions to part with GRMC were apparent), and Mr. Marks still pitched a positive financial situation. Then, by April, the doom and gloom was pitched. Mr. Marks says what he needs to and we good ole folks hear what we want to (including at the town hall meetings).
Now about # 2. What's the difference between $35 and $500? About 15 miles. But why don't we just stay ignorant to that one.
#6, maybe later I will divulge, maybe never.
Of course GRMC and the surrounding hospitals are in competition with each other.
Monopoly? There's not enough market share in this tiny county to bring in something like a private laboratory. Also, one can chose to go to HM Erath, HM Cleburne, Lake Granbury or the metroplex.
Lab and X-ray: it costs a fortune to purchase the instrumentation for these services and to pay accredited personnel to operate them. Also, these areas are heavily regulated by the government and must meet stringent requirements and frequent proficiency inspections and testing of methods and personnel. Of course a lab such as Quest can offer the lowest price due to its high volume. However, there are other issues when using a lab such as this, like how much was the specimen quality compromised while in transit to this lab? Also, you may remember a recent artlcle that Quest had been turning out erroneous Vitamin D results for a year.
Pecan Plantation: I assume that GRMC decided to branch out with the clinic in Pecan since so many residents from that area were already using our doctors and GRMC as their hospital.
Lake Granbury: I have worked for the corporation that owns Lake Granbury (Community Hospital Systems) in the past. It was the only job I have ever resigned from because the level of mismanagement and incompetence had become so intolerable.
Keep up the good discussion, everyone.
humanbeing, I am with you. It is good to have healthy discussion.
It is true that hospitals are in competition with each other. But Glen Rose does NOT have healthy competition for people to choose from. And if people knew how much money they could save, they would probably head to Granbury, Cleburne, even Fort Worth or Dallas or Waco or Temple even Lubbock or Houston. When it comes to ingrequent procedures, gas is cheaper, even last year, than the price differences for "ambulatory" services.
And my point about LGMC is that Mr. Marks and select commissioners won't admit that private, for profit management is an option. Didn't I hear audio of someone asking Mr. Marks if Hospital District was the only option. I was suprised to next hear Mr. Marks say that there was no other option. Well, keeping my point, LGMC is private and for profit and all of that other unmentioned option, and LGMC must be doing something right, because it appears that Mr. Marks is scared of their competition. Sounds to me that one of the two is quite the competitor while the other needs to stay on the porch.
How many doctors has GRMC recruited away from LGMC? Hmm. How is it that LGMC appears to be growing its physician group and spreading its wings across Hood County and even over into Glen Rose, if they are so mismanaged? Do you have any opinion about GRMC's management principles? Do they compare to LGMC's or what?
Now about Pecan Plantation, I just do not see things being as simple as you seem to think they are.
Now, about Glen Rose's future, have you not heard that Luminant has applied for permission to install 2 new units? Have you noticed how many presently empty hotels there are in Glen Rose? Somebody knows something. They are expecting growth. I know a lot of people do not want Glen Rose to grow, but it can't be prevented (except with high taxes). GRMC, too, is anticipating growth. The problem is that GRMC is positioning itself for monopoly. If GRMC were not relying on our tax money, and they could compete so pwerfully, I would have no complaint. But I foresee Glen Rose trying to grow up with a single, government-funded entity enjoying its carefully planned monopoly. GRMC will hold back healthy development of private competition.
And I do realize that either way the vote goes, GRMF dba GRMC is still going to be funded by our taxes. Like I said before, the hospital district is merely a moot point. It truly boils down to approval of how sloppy things have been handled. I cannot approve.


iWeb page summary not in google.
Discussion in 'Mac Apps and Mac App Store' started by impulse462, Nov 13, 2009.
and when I use that, I put it in the 'Header' of the page. So the problem then is when I publish it, and search again on google and my page comes up, there is no new description. So, if any of you have had experience with this and know how to get it so my page summary comes up when my page is searched, that would be awesome.
Meta tags really have little impact on getting google to notice and categorize it now a days. iWeb is not really SEO friendly because the bots cannot easily traverse the site. That being the case iWeb sites don't get added very quickly.
Google doesn't reindex a web site that often, but you also can't control what the description will be that Google shows in search results. Google decides that.


text:
Limited Edition Ivor the Engine Stamp Sheet
It's hard to believe but everyone's favourite little green train from the top left hand corner of Wales, Ivor The Engine, is 50 years old this year! To celebrate his birthday, co-creator Peter Firmin has worked with leading philatelic specialists, Buckingham Covers, to produce this delightful limited edition stamp sheet.
The highly-collectable A4-sized sheet features genuine Royal Mail stamps as well as charming images from the series and are available as Presentation Packs (complete with information card) or mounted, ready for framing. A small number have been personally signed by Peter Firmin himself.
The sheet is raising funds for Peter's favourite charity, SPANA (the Society for the Protection of Animals Abroad) which supports people in developing countries by helping them look after their working animals. Fans of Ivor will remember Bluebell the Donkey who ambles in the Welsh fields (and features on the stamp sheet design) but Simon Pope, Communications Director at SPANA, is keen to point out that not all donkeys have it so easy. "In many countries, working animals can suffer terrible cruelty, not because their owners don't care but because they don't know any better. And yet, without their animals, families could starve," he explains, "The funds raised by Ivor the Engine and this collectable stamp sheet will go towards veterinary treatment for working animals overseas and will fund education projects to teach better animal care".
Only 1959 sheets in total have been printed (including the signed versions) so they really are a must-have for anyone who loves Ivor.
In addition to the stamp sheet, Buckingham Covers is also producing a First Day Cover (collectable envelope) in June 2009, featuring one of Ivor's friends, Idris the Dragon. The cover will feature Royal Mail's "Mythical Creatures" stamps (they don't come more mythical than a dragon!), issued on 16th June 2009 and will be postmarked on the day the stamps are issued (which is why they're called "First Day" covers). Idris will also be helping to raise funds for SPANA and Peter will be signing a small number of these too.
The stamp sheet and cover together will make a charming pair that you'll treasure for years to come, so don't miss out - order yours today! The Ivor 50th Anniversary Stamp Sheet Presentation Pack is £26.95 or £39.95 if personally signed by Peter Firmin. Collectors can have theirs mounted ready to frame for an additional £5. The Idris cover is available unsigned at £10.95 or £24.95 if personally signed by Peter Firmin.
To place your order, you can order the Stamp Sheet or Idris Cover via these links or you can call Buckingham Covers directly on 01303 278 137 - let them know you've come from the Smallfilms Treasury.


Police are currently investigating some reports of hate speech circulating on social media which has become a growing concern in the country.
Police Commissioner Brigadier General Sitiveni Qiliho says with general election nearing, posts that can likely spread hatred are increasing.
The Police Commissioner says hate speeches mostly posted from fake accounts are troubling as it can lead to other issues which can incite people to conduct criminal acts.
The Police Chief says people can give their views or criticize policies… but posts that can create tension will be dealt with by the force.
This was well received by Director of Human Rights and Anti-Discrimination Commission Ashwin Raj adding people spreading and advocating hate speech are taken to task and face the full brunt of the law.
He also slammed those posting hate speeches claiming they're not from ordinary Fijians.
Raj has also confirmed they have received numerous reports against hate speech which have been forwarded to the Police.
The public is also urged to lodge a complaint if they come across any such post.


text:
module ClassExamples {

    class Greeter {
        static defaultGreeting = "Hello, there";
        greeting: string;
        constructor() {
            console.log("Running the constructor...");
        }
        greet() {
            if (this.greeting) {
                return "Hello, " + this.greeting;
            }
            else {
                return Greeter.defaultGreeting;
            }
        }
    }

    var greeter1: Greeter = new Greeter();
    console.log(greeter1.greet());

    var greeterMaker: typeof Greeter = Greeter;
    greeterMaker.defaultGreeting = "Hey there!";

    var greeter2: Greeter = new greeterMaker();
    console.log(greeter2.greet());

    var greeter3: Greeter = new Greeter();
    greeter3.greeting = "world";
    console.log(greeter3.greet());

    class Point {
        x: number;
        y: number;
    }

    interface Point3d extends Point {
        z: number;
    }

    var point3d: Point3d = { x: 1, y: 2, z: 3 };

}


Quality PC port, including graphics and control options.
The game has a built-in benchmark mode which can be accessed through launcher in Advanced menu. On Linux however, you must add DefaultPCBenchmarkMap.xcmap -unattended into the Launch Options to access it.
Aim assist is on by default even when not using a controller, but can be fixed.
Extract to the installation folder and replace all files.
May cause game to enter an infinite loading loop. If it does, turn texture streaming back on, leave that area of the game, and turn it off again once you leave the area.
Exiting to desktop or main menu reveals the local date of the last checkpoint.
Key mappings are encrypted which prevents sharing key bind files or creating custom commands.
Game creates an automatic permanent save at the beginning of each chapter. These saves are automatically overwritten if replaying from a previous chapter.
Full 3xLandscape. HUD may not be centred by default; see Multi-monitor.
GUI may be too small. See GUI scaling on high resolution displays.
Limited FOV adjustment of 15º. See Field of view (FOV).
On Windows, set fullscreen mode to "Fullscreen (Windowed)".
Option is called "Lock Framerate".
The HUD may not be centred automatically for multi-monitor setups.
Change SafeRectX0 and SafeRectX1 to area you want to HUD to be within.
Change SafeRectY1 to the height of your monitors.
There is a FOV slider in the game options, however it only increases/decreases FOV by 15% from the default value of 70º (59.5º - 80.5º).
Locate line MaxUserFOVOffsetPercent=15.000000 and change its value to 100 for maximum variability. This value is in percent and not degrees. See table below for precise field of view values.
Start the game and set your field of view via slider in menu.
Default FOV slider to the max.
Slider offset set to 100 and slider set to the max.
Some of the post-processing effects can only be disabled in the game's XEngine.ini file. These effects include depth of field, light bloom, and color correction.
Some keys cannot be rebound in the Burial at Sea DLC. "F" is always "take all" when looting. ↵ Enter, ← Backspace, Tab ↹, and Esc are reserved for menu commands and cannot be bound.
Precise customization only available through INI edits.
Slider for mouse speed is set to very wide range, which can be unsuitable for high precision mice.
Start the game and set your desired sensitivity via slider.
This fix will modify the in-game slider and give better control.
Master, music, SFX and voice.
Auto configures up to 5.0 output.
Linux only. In alsoft-config set HRTF Mode to Force On at the HRTF tab.
Use Helix Mod: Bioshock Infinite.
There have been reports of crashing and freezing, possibly related to i7 processors. 2K is aware of this issue and there should be patch soon.
If the game crashes on start-up, disable any on-screen display applications like MSI Afterburner.
Disable overclocking or underclock your graphics card.
Disable Killer e2200 PCI-E Gigabit Ethernet Controller or any other virtual/VPN network adapters like Hamachi.
When the game can't detect or detects wrong video memory size, it automatically enables only Very Low and Low options for texture quality.
There is also an issue on some systems that selection Very High or Ultra for texture quality will cause to textures never load properly and game tries to load them over and over.
Nvidia cards experience FPS drops in certain areas when Dynamic Shadows is set to Very High or Ultra.
Aim assist is on by default even when using keyboard and mouse.
There are some auto aim variables in the .ini files but these variables are reverted to True every time you start the game. There is no permanent fix yet.
This fix affects user options configurations, if you need to make a config in game do it before try this.
Save your changes and make XUserOptions.ini read only.
This fix needs to be applied every time the game is started.
Start the game with a controller plugged in.
Go to controller options and turn off Aim Assist.
Unplug controller and play the game.
GUI elements are not scaling with resolution which makes these elements rather small on high resolution displays.
Locate lines MaxResolutionUpScale=0.0 and change value to something between 0.0 and 1.0. See screenshots for examples.
Run the game with the -windowed command line argument.
Open the graphics options and set the game to run full screen.
Close the game, remove the launch option, then restart the game.
Let application create sample script. This script file should open after installation.
Delete everything and insert the lines below.
Open AutoHotkey window (green H icon in tray area), navigate to File and hit Reload Script.
This is script for default bindings where aiming is bind to middle mouse button. For aiming by right mouse button replace MButton for RButton.
For bindings to other keys, see Hotkeys and KeyList sections of AutoHotkey documentation for button syntaxes.
If your zoom gets stuck, you can reset with the run key.
Right-click on BioShockInfinite.exe, go to the compatibility tab, tick the box and select Windows Vista Service Pack 2.
Set the PoolSize variable in XEngine.ini to about 400 less than the total number of Megabytes RAM your video card has (e.g if you have 2048 MB of video RAM set this to 1600).
Add this launch option in Steam: -ReadTexturePoolFromIni.
Bioshock Infinite auto-detects any controllers/joysticks attached to the system including virtual ones. This could make the game uncontrollable, cause the camera to spin, and label the menu with Xbox prompts.
Remove all physical controllers and joysticks.
Disable virtual adapter for 3DConnexion devices.
To disable controller support, edit %USERPROFILE%\Documents\My Games\BioShock Infinite\XGame\Config\XEngine.ini and change AllowJoystickInput=1 to AllowJoystickInput=0. Save your changes.
These forms of V-Sync significantly reduce micro-stuttering.
For Nvidia cards, Adaptive V-Sync can be enabled through the driver control panel. Set Vertical sync to Adaptive.
For AMD cards, Dynamic V-Sync can be enabled using the third-party program RadeonPro. Click the Add new profile icon and find the BioShock Infinite executable (BioShockInfinite.exe in <path-to-game>\Binaries\Win32\BioShockInfinite.exe). Click the newly created profile and click the Tweaks tab. Set VSync Control to Always on. Enable Dynamic Framerate Control and set Keep up to to 60.
Mice with high polling rates can sometimes cause microstuttering.
Click on the "Performance" tab.
Change the "Polling Rate" to 125 Hz.
Launch the game with --eon_force_display=#, replacing # with the index of the monitor you want the game to launch on.
In a multi-monitor configuration where 1 monitor is portrait and 1 monitor landscape and where game starts on portrait monitor and is forced to run on the landscape monitor using --eon_force_display, game does not recognize landscape monitor's aspect ratio and will only allow portrait aspect ratios/resolutions.
No real fix is available at this time.
De-rotating the portrait screen will allow selection of landscape aspect ratios, but it is not persistent. The portrait monitor must be de-rotated before playing as a workaround.
In XUserOptions.ini setting ResolutionX=<DesiredWidth>, ResolutionY=<DesiredHeight>, and DisplayMode=0 (fullscreen) will allow the game to run in widescreen, but you are restricted to fullscreen play.
The game uses mouse acceleration, even if mouse acceleration is turned off in-game.
This will disable mouse acceleration in your system before launching the game and enable it again when the game closes (which might take a couple of seconds).
Graphical user interfaces for mouse settings (e.g. mate-mouse-properties) might not be aware of the changes. It's best not to touch them while the game is running.
3.3, 4.1, 4.2 3.3 on OS X, 4.1/4.2 on Linux.
SDL Linux only, for gamepads.
This page was last edited on 25 April 2019, at 22:43.


text:
``COT.platforms.cisco_nxosv`` module
====================================

.. automodule:: COT.platforms.cisco_nxosv


text:
Q: Can I inherit "set +h" to a sub process? I seem unable to inherit the effect of set +h to a called shell script:
Here is a shell script (./call).
#!/bin/bash

set +h
export SHELLOPTS

./called

And here is the contents of ./called:
#!/bin/bash

echo \$-=$-
echo SHELLOPTS=$SHELLOPTS

When I execute ./call, the following is printed:
$-=hB
SHELLOPTS=braceexpand:hashall:interactive-comments

I thought that shell options are inherited when I export SHELLOPTS. This is apparently not the case.
Is there a way to inherit the effect of set +h to a called shell script?

A: From the bash manual:

The options appearing in SHELLOPTS are those reported as 'on' by 'set
  -o'.  If this variable is in the environment when Bash starts up, each
  shell option in the list will be enabled before reading any startup
  files.

It follows that options turned off do not show up in SHELLOPTS, and so has no effect on whether the new shell enables or disables them.
You could try either of:

*

*run the script with bash +h ./called, or

*put set +h in a file, set BASH_ENV to the path of that file and export it, thought this will affect all instances of bash started down the line unless one of those unsets or unexports it.

redpajama_set_name: RedPajamaStackExchange


text:
Tetlow (Sonia)
Sonia Tetlow
Sonia Tetlow's latest record, "better days," was released October 25 2022. Recorded mostly live at Marigny Studios (New Orleans) over a long weekend during the summer of 2022, the album captures the spontaneous joy of veteran musicians coming together to create after years of pandemic isolation. Paul Sanchez produced the record and brought
Sonia Tetlow's latest record, "better days," was released October 25 2022. Recorded mostly live at Marigny Studios (New Orleans) over a long weekend during the summer of 2022, the album captures the spontaneous joy of veteran musicians coming together to create after years of pandemic isolation. Paul Sanchez produced the record and brought together Mary Lasseigne on bass and harmony vocals, Glenn Hartman on keys, Jonathan Pretus on electric guitar, percussion, and harmony vocals, and Andre Bohren on drums, lap steel, harmony vocals, and percussion. Tetlow played acoustic guitar, mandolin, and tenor banjo and sang lead vocal. Ben Lorio engineered the session, and the atmosphere in the studio was open and joyous and a beautiful creative collaboration ensued. Though everyone had played together as individuals in some capacity over the years, the first time everyone played together as a band was when the session began. Three days later they had recorded 11 songs (10 Tetlow originals and 1 song by Paul Sanchez).
After years of creating in fits and starts as Tetlow (and everyone else) navigated the challenging and thwarting environment of the pandemic, the intention behind making this album was to create a little more light in the world. The songs range from meditations and reflections to poking fun and persisting. If listeners experience even a fraction of the joy that went into the making, "better days" will help to make some better days indeed.
better days 4:45
be the light 3:14
happy just to be 5:23
been tryin to tell ya 3:10
come what may 3:34
foolin me 4:06
in our hands 3:45
kicked the covid 3:32
take a breath 4:49
won't give in 4:57
lost heart 3:49
A rockin' and rollin' classic Tetlow tune reimagined with the band she recorded her 2017 album "Now" with.
An electric, pulsing, and fresh soundscape, Sonia Tetlow's new album is an uncompromising and uplifting rock 'n roll nod to the possibility of "Now."
Sonia Tetlow is musician who studies the craft of song, a songwriter who performs with abandon, giving herself freely to the moment of live music making. While Tetlow's music career has spanned from
Sonia Tetlow is musician who studies the craft of song, a songwriter who performs with abandon, giving herself freely to the moment of live music making. While Tetlow's music career has spanned from "punker snarls to banjo pickin' reflection," she has always been a rock and roller at heart. It's been three years since Tetlow has released a solo record (A Place for Everyone, November 2014), and roughly one year since she announced her departure from alterna-grass band Roxie Watson. Her new record, "Now," signals a new era for Tetlow.
Though the breadth of her musical journey shines through, there is no room for compromise--this is Tetlow at her purest, in songwriting and soundscape. "I've never been afraid to put it all out there in song," she comments. Heavy topics, such as the passing of Tetlow's father earlier this year, clearly inform a number of the songs on the record; yet many, including "Now," ring determined, hopeful, uplifting. "Essentially ["Now"] is a song that's about trying to get out of my own way," she explains. "It's the last song that I wrote for the album and it made sense that it would sort of culminate in that...a lot of these songs are about reconciling with the past and trying to live in the moment and be at peace with it."
Josh Birmingham – drums, percussion, harmony vocals Luke Campolieta – additional guitars Matt Henderson – Rhodes keyboard, Moog synth Jimmy "Bones" McAlpin – electric guitar Amy Ray – harmony vocals Seersha – harmony vocals Sonia Tetlow – acoustic guitar, vocals Ben Williams – bass, harmony vocals
Amy Ray appears courtesy of Indigo Girls on "Hard Fought Year" and "Tripline"
Album design by Amy Mann Produced by Ben Williams Engineered by Luke Campolieta Recorded at The Zone (Norcross, Georgia) All songs by Sonia Tetlow. ©2017
Now 3:51
Hard Fought Year 4:35
That's Alright by Me 3:42
Slow Burning 5:14
Inside Out 4:01
Tripline 5:28
Trick Coin 2:49
Numb 4:55
Don't Hold Me to It 2:53
Grains of Sand 4:03
A Place for Everyone
Recorded half in New Orleans and half in Atlanta this collection of songs combines the musical landscapes and communities of both cities into one album, featuring performances by Amy Ray, Paul Sanchez, Craig Klein, Michelle Malone and many more.
Own Way Home
Recorded at Piety Studios in New Orleans, Own Way Home, mixes indie rock angst with NOLA grooves and the poetry of Sonia Tetlow's songwriting. Featuring guest appearances by some of NOLA's finest musicians, including Shamarr Allen, Paul Sanchez and more!
Herman Put Down the Gun
"Songwriting at its absolute best. The imagery is stunning" -- Georgianne Nienaber, The Huffington Post.
Comprised of former members of Cowboy Mouth, Michelle Malone and the Low Down Georgia Revue and STB, Herman Put Down The Gun is a band based on songs and the swelling sounds that bring them to life; harmony, melody, the sweet soul, the rock
Comprised of former members of Cowboy Mouth, Michelle Malone and the Low Down Georgia Revue and STB, Herman Put Down The Gun is a band based on songs and the swelling sounds that bring them to life; harmony, melody, the sweet soul, the rock edge. In a tradition reminiscent of the The Pretenders, Herman creates music that hints at different genres while always sounding uniquely their own, a blend they like to call Rockit-Pop.
Herman formed in Atlanta in December 2007 when friends Sonia Tetlow, Lee Kennedy & Linda Bolley decided to get together and make the music they wanted in the way they wanted, together as a collaborative band. Each brings their stellar musicianship and unique voice to the ever-evolving sound of the group.
A couple of months after forming, Herman was given the opportunity to spend a weekend at a studio in New Orleans and quickly recorded ten songs. These songs are a snapshot of the band at its beginning and a glimpse of where it's heading.
from a seed of sand
Organic and musical, melodies of voice and guitar woven into portraits of sound, poems of song.
Rockin' by night and writing by day, her latest solo effort, "From a Seed of Sand," was written on the back of the tour bus while Tetlow toured as the bass player for New Orleans rockers, Cowboy Mouth. Day by day, town by town as the muses struck and
Rockin' by night and writing by day, her latest solo effort, "From a Seed of Sand," was written on the back of the tour bus while Tetlow toured as the bass player for New Orleans rockers, Cowboy Mouth. Day by day, town by town as the muses struck and the music flowed, the songs came together. She recorded it song at a time whenever the CM tour schedule afforded her some time in the studio.
Called, "mellow but soulfully intoxicating," by Atlanta's Stomp and Stammer magazine, "From a Seed of Sand" reflects Tetlow's continued growth as a musician and songwriter. With this album, she approached each song like a canvas, painting the different colors of sound with the voices of each instrument. At once both a contrast to earlier works like "Spit" and "Swerve," and a clear evolution of the same artistic vision, "From a Seed of Sand" seduces the listener with sounds and space that both lull and stir. With beautiful and intricate guitar work and lyrics both plain and poetic, this album soars, honestly, humanly, in that magic way that music does when left alone to breathe.
"Soaring pipes and equally snarling guitar work... tight-as-a-noose approach and knack for well thought upon lyrical ins-and-outs.." Michael Andrews, FLAGPOLE
"Atlanta's Sonia Tetlow Band, or "STB" for those like myself cursed with marginal rather than total recall, is the proud parent of a fiery new long-player it has christened Swerve. Comprised
"Atlanta's Sonia Tetlow Band, or "STB" for those like myself cursed with marginal rather than total recall, is the proud parent of a fiery new long-player it has christened Swerve. Comprised of Ms. Tetlow, holding down both guitar and vocal duties, bassist Lee Kennedy and drummer Becky Shaw, the powerful STB prefers its rock and roll be prepared from scratch, using only the basic ingredients, leaving no fat behind on its plate. In the process of cranking out inspired tunes-a-plenty, the band also manages to breathe much-needed new life into the rapidly stagnating pool of power trios that matter." -- FLAGPOLE
"More like super-charged poetry than standard rock and roll fare, STB has been compared to Patti Smith, Siouxsie & the Banshees, the Stooges, and early Pretenders... Comparisons fail to do justice, however, to STB's undeniable individuality... With Becky Shaw on drums laying down incessant rhythmic hooks, Lee Kennedy playing sinuous, soul-infused bass, and Sonia Tetlow's edgy guitar and vocals soaring over the whole thing, STB delivers a riveting show from start to finish." -- ROCKRGRL Magazine (Sept/ Oct 2001)
"Slaps your face like the first time you heard Patti Smith blow dust out of the radio." -- Hal Horowitz, Atlanta Press Magazine
"Those who missed the late-70's and early-80's explosion of often exhilarating alternative music - then called punk although in retrospect it wasn't all that punky - can relive those heady years when listening to this
"Those who missed the late-70's and early-80's explosion of often exhilarating alternative music - then called punk although in retrospect it wasn't all that punky - can relive those heady years when listening to this incredibly accomplished debut release. Atlanta's Sonia Tetlow Band, reduced to their initials, grab wiry, edgy melodies and wrap them around a tight three-piece that knows when to play loud and when to lay back, resulting in an album as incendiary as the first Pretenders disc of anything I've heard in the 20 years since.
Tetlow's husky voice, a ringer for a Chrissy Hynde/ Siouxie Sioux combination, alternately sputters and purrs, driving the songs down a bumpy road they call agit-pop, while making the most of a three-piece lineup. Even without printed lyrics, you'll be able to sing every one of these songs after the first listen, but it's the raging energy here, especially exemplified by bassist Lee Kennedy's jazz-like adeptness, that slaps your face like the first time you heard Patti Smith blow dust out of the radio.
Poetic, tuneful and, above all, rocking with a barely contained intensity, the STB locks into a groove and hangs it tight. Whether it's the grinding, slowly creeping closing track "Night" of the crisp brevity of "Running Out of Time," this album is as timeless as the best, and most classic releases of punk's early hey-day. Ignore the blurry cover, nondescript art, blandly initialed band moniker and vaguely offensive title, and dig into one of the most powerful first albums from an Atlanta band in years." -- Hal Horowitz" - (Above review by Hal Horowitz, Atlanta Press)
"Snarling, frantic, yet downright majestic." - (Jeff Clark, Stomp And Stammer)
"Sonia Tetlow is a little package of high explosives with a short fuse. Her full-length debut as STB is a surprisingly powerful collection of edgy and agitated rock music which finds her singing in world-weary voice." - (Lee Smith, Southeast Performer)


Ready for your close-up? Our team is ready! At Marketing and Design With Color, that's what we strive to do every day. You won't find a dull day in our lives, because we believe life is too short for beige & boring!
We offer professional HD video production, the perfect tool to get you noticed across the world!
From start to finish, our team is here to ensure the highest quality production! Our services include: preparation for filming, coordinating models & their "look", creating the storyline and scripts, on-site coordination during filming, staging of all shots, props & materials, video editing, and of course… online marketing – We'll upload your finished product to your website, your YouTube Channel, Facebook page & more! Call us today!!


Why is there so much missing data in the 1980 Census owner cost (OWNCOST) variable?
The OWNCOST variable of homeowner expenses is listed as available for the 1980 Census, but much of the data is missing. Over 13 million owner households have missing cost data, or about one quarter of all owner households, severely limiting the usefulness of the remaining data. Is there a reason why this data is missing and is it available anywhere else? All the 1980 Census samples have the same problem.
Make sure you account for the codes that represent non-response (recoding them to zero). You will then need to separate households with codes of zero that should not be in the questions universe. Doing this I end up with 10,133 owner occupied households that have OWNCOST==0 (which is also strange as we would not expect any eligible households to have zero monthly cost). You may wish to contact the Census Bureau directly, referencing the variables by their original Census name, and ask if this is a known issue.